Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia : Where do we stand?
© 2022 John Wiley & Sons Ltd..
Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Hematological oncology - 40(2022), 5 vom: 04. Dez., Seite 835-842 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
D'Arena, Giovanni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic lymphocytic leukemia |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 15.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.3037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341889040 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341889040 | ||
| 003 | DE-627 | ||
| 005 | 20231226012817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.3037 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341889040 | ||
| 035 | |a (NLM)35667043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a D'Arena, Giovanni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia |b Where do we stand? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic lymphocytic leukemia | |
| 650 | 4 | |a flow cytometry | |
| 650 | 4 | |a measurable residual disease | |
| 700 | 1 | |a Sgambato, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Volpe, Silvestro |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Amodeo, Rachele |e verfasserin |4 aut | |
| 700 | 1 | |a Tirino, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Auria, Fiorella |e verfasserin |4 aut | |
| 700 | 1 | |a Statuto, Teodora |e verfasserin |4 aut | |
| 700 | 1 | |a Valvano, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrantuono, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Deaglio, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Efremov, Dimitar |e verfasserin |4 aut | |
| 700 | 1 | |a Laurenti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Aiello, Antonella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 40(2022), 5 vom: 04. Dez., Seite 835-842 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:5 |g day:04 |g month:12 |g pages:835-842 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.3037 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 5 |b 04 |c 12 |h 835-842 | ||